Press Release June 17, 2014

Goodwin Procter Wins Major Patent Victory for Roxane and Cipla

Goodwin’s patent litigators recently won a significant bench trial for clients Roxane Laboratories, Inc. and Cipla Ltd. in which the court invalidated the last patent blocking the commercial launch of the first generic treatment for diarrhea-predominant irritable bowel syndrome (IBS-D). The case was brought by Prometheus Laboratories and related to Roxane’s alosetron product for the treatment of IBS-D.

This trial victory marks the conclusion of more than three years of litigation regarding alosetron and follows earlier victories for Goodwin on behalf of Roxane and Cipla at the claim construction stage that contributed to dismissal of one of the patents in suit and narrowed the issues presented to the Court on the remaining patent.

The Goodwin team was led by IP litigation partner Keith Zullow.